Major risks clear as growth plan expands
- Q2 2026 revenue rose 20.1% year over year to $224.2 million.
- Management raised 2026 revenue guidance to $880 million to $890 million and adjusted EBITDA margin to 13% to 14%.
- The company acquired VitalConnect for multi-vital monitoring and a broader mobile cardiac telemetry strategy.
- Medicare finalized coverage rules favorably, and the company settled litigation with Baxter for $50 million.
- FDA clearance for the third-generation AI algorithm locks in a major margin improvement path.
- The DOJ Civil Investigative Demand and an unresolved FDA warning letter are the main remaining risks.
A cleaner story and a new growth engine
iRhythm has systematically removed many of the storm clouds that hung over its business. The third-generation AI algorithm received FDA clearance, locking in a path to save $100 million in costs over five years. Medicare finalized coverage rules without limiting access, removing a major reimbursement overhang. Finally, the company paid $50 million to settle a legal fight with Baxter. With these out of the way, the underlying strength of the business is easier to see.
That underlying strength is significant. Q2 2026 revenue grew 20.1% to $224.2 million, and management raised full-year guidance for both sales and profit margins. The acquisition of VitalConnect adds new growth potential. VitalConnect brings multi-vital sensors and 30-day monitoring, which lets iRhythm target the half of the mobile cardiac telemetry market it could not reach before.
The bear case is now focused tightly on regulatory history. The DOJ is still investigating claims for the Zio AT product, and the scope of potential financial penalties is unknown. The company is also waiting for the FDA to officially close a May 2023 warning letter after completing a third-party audit. Commercial execution is another factor to watch, as the sales team must integrate the VitalPatch launch in 2027 while preparing for the new Zio MCT rollout.
Finn's low valuation score reflects a stock that demands perfection. The business is executing well and removing hurdles, but investors are already paying a premium for that progress.
A patch, a report, and a payer
iRhythm makes money when a licensed health care provider orders a Zio service for a patient. The patient wears a small wireless patch that records heart rhythm data. iRhythm then processes the data through its cloud system and delivers a report to the clinician.
Most revenue comes from third-party payers, including commercial insurers and Medicare. In Q1 2026, contracted third-party payors were 53% of revenue and CMS was 26%. Health care institutions were 15%, and non-contracted third-party payors were 6%.
The platform is expanding beyond single-focus cardiac monitoring. The VitalConnect acquisition adds sensors that track temperature and respiratory rate alongside heart data. This allows iRhythm to move into new areas like in-hospital monitoring and hospital-to-home programs.
Zio is the center
Zio Monitor
Zio Monitor is the core extended Holter service. The patch records ECG data for up to 14 days, then iRhythm turns that data into a report for the doctor.
Zio AT
Zio AT adds mobile cardiac telemetry for higher-acuity monitoring. It is also the product tied to the DOJ reimbursement investigation, so it carries both growth value and legal risk.
VitalPatch
Acquired through VitalConnect, this platform offers up to 30 days of monitoring and multi-vital sensors to address the broader mobile cardiac telemetry market.
Traditional Holter services
Traditional Holter monitoring gives iRhythm a place in older monitoring workflows. It is less exciting than long-term patch monitoring, but it helps keep the service suite complete.
Next-generation Zio MCT
The next-generation mobile cardiac telemetry product is planned for launch in the first half of 2027. It could help iRhythm compete for more high-acuity monitoring volume.
Third-generation AI algorithm
Now FDA-cleared, this algorithm will roll out in the first half of 2027. Management expects it to reduce clinical technician review time by up to 50% across the Zio platform.
Revenue by payer
iRhythm reports one operating segment. This mix is by payer type for the three months ended March 31, 2026, so it shows who paid, not separate business lines.
What could go wrong
DOJ review of Zio AT claims
High impact · Medium oddsThe DOJ Civil Investigative Demand focuses on Zio AT reimbursement. The exact scope and possible financial exposure are still unknown. A settlement, billing change, or wider probe could hurt cash flow and trust.
FDA warning-letter cleanup
High impact · Medium oddsiRhythm completed a third-party audit but is still working to resolve a May 2023 FDA warning letter. Slow remediation or further observations could delay products and keep the risk premium high.
Dual-product launch integration
Medium impact · Medium oddsThe company must integrate the VitalPatch rollout into its sales force in early 2027 while preparing to launch the organic Zio MCT product. Doing both at once creates a risk of sales force confusion or product cannibalization.
High expectations in the stock
Medium impact · High oddsFinn's valuation score is low, which means the market price already gives iRhythm credit for a better future. If revenue growth slows, margins stall, or legal news worsens, the stock could react sharply.
In one breath
What does iRhythm Technologies do?
iRhythm provides remote cardiac monitoring services. Its Zio patch records heart rhythm data, and its cloud platform helps turn that data into reports doctors use.
How does iRhythm make money?
Most money comes from reimbursement by commercial insurers and Medicare after a doctor orders a Zio service. A smaller share comes from health care institutions.
Why did iRhythm buy VitalConnect?
The acquisition adds multi-vital sensors and 30-day monitoring to the platform. This lets iRhythm compete for a larger share of the mobile cardiac telemetry market.
What is the next big catalyst for IRTC?
The rollout of the newly cleared third-generation AI algorithm and the integration of VitalConnect products in early 2027 are the next major milestones.
